Navigation Links
QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR
Date:9/1/2010

analgesic effects of flexible dose versus fixed low dose of MoxDuo IR over a 48 hour study period. Since the blinded interim analysis was based on how much variability was observed when both dosage groups were combined and did not evaluate the magnitude of the difference between the two treatment groups per se, one must be cautious in drawing conclusions that the expected endpoints will be met. This type of interim analysis conducted for the purpose of sample size re-estimation, which was accepted by the FDA, does not result in a statistical penalty in the p-values of the final analysis to be conducted upon study completion.For more information please contact:Dr John W HoladayManaging Director and Chief Executive OfficerTel: +1 301 908 3086Email: john.holaday@qrxpharma.comChris J CampbellChief Financial Officer and Company SecretaryTel: +61 2 9492 8021Email: chris.campbell@qrxpharma.comForward Looking StatementsThis release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainti
'/>"/>
SOURCE QRXPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... SAN FRANCISCO , Aug. 3, 2015  Sage ... generation of portable laboratory-quality cannabis potency measurement systems, announced ... PAC Bay Area Cruise Fundraiser. A limited number of ... the festivities and help a great cause while enjoying ... a scenic cruise around the San Francisco Bay at ...
(Date:8/3/2015)... -- Depomed, Inc. (NASDAQ: DEPO ) ("Depomed" or the ... HZNP ) ("Horizon") announcement that it intends to request ... record date to determine the shareholders eligible to request ... will review the request when it is received. Provided ... information required under Depomed,s bylaws, the Depomed Board will, ...
(Date:8/3/2015)... NEW YORK , August 3, 2015 /PRNewswire/ ... report published by Persistence Market Research "Global Market ... to Witness Highest Growth by 2022", ... at US$15 Bn by the end of 2015 and ... 6.8% from 2015 to 2022, to account for ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4
... PRO-DEX, INC. (Nasdaq: PDEX ) invites investors and ... fiscal 2012 first quarter financial results. (Logo:   ... be broadcast live over the internet on Wednesday, November 9, ... and may be accessed by visiting the Company,s website at ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... were published in Obesity, the peer-reviewed journal of The ... the investigational drug Qnexa in 1,267 severely obese (BMI >/= 35 ... addition to average weight loss of 14.4% of initial body weight ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Financial Results Conference Call and Webcast 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 3Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 4Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 5Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 6
(Date:8/3/2015)... ... ... Since 1978, the number of black males applying to and attending medical school ... AAMC (Association of American Medical Colleges). , Despite an overall increase in the ... black male applicants to medical school dropped to 1,337 in 2014 (from 1,410 in ...
(Date:8/3/2015)... ... ... The Workgroup for Electronic Data Interchange ( WEDI ), the nation’s leading nonprofit ... announced the release of its findings from its June 2015 ICD-10 Industry Readiness Survey. ... survey results and recommendations , strongly encouraging the department to continue to ...
(Date:8/3/2015)... ... August 03, 2015 , ... According to an opinion piece published July 28 by ... to one pound of weight loss may not be accurate. While this system may work ... pound of fat varies – based both on the individual and at what point that ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... Bayer has ... and Yasmin related claims in which a claimant alleged to have suffered an arterial ... to the birth control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B Awards celebrate ... BESLER Consulting's campaign for the launch of their Readmissions Analytics product was selected ...
Breaking Medicine News(10 mins):Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2
... Ciara, Kelly Rowland, Common, Romeo and Lyfe ... ... that,their award-winning national HIV/AIDS public information campaign with the,Kaiser Family Foundation, Rap-It-Up ... KNOW BOUT THAT? RAP-IT-UP SEX,QUIZ" slated to premiere on Monday, November 5 ...
... Hundreds of Local Kidney Patients Requiring,Dialysis; More ... Disease, EL SEGUNDO, Calif. Nov. 2 ... of dialysis services in the,United States, announced today ... the Fargo-Moorhead area -- increasing the number of,outpatient ...
... flexibility and cost-control, SOUTH PORTLAND, Maine, Nov. ... health insurance options of much larger businesses. Anthem,Blue ... portfolio of eleven,insurance plans for small businesses (50 ... insurance products provide more health insurance,choices than have ...
... to other groups, study says , FRIDAY, Nov. 2 ... for post-traumatic stress disorder (PTSD) shows promise, according to ... The American Journal of Psychiatry . , The study ... to an Internet-based, eight-week program of self-management CBT no ...
... 2 RHEI Pharmaceuticals, Inc., a,fully integrated specialty ... China market, will be presenting, at the,Acumen BioFin ... Monday,November 5, 2007 at 2:20 p.m., eastern. ... any,company wishing to gain access to the fastest ...
... Mammography Van Features ... NovationDR Digital System, MALVERN, Pa., Nov. 2 ... digital mammography,system in the U.S. The MAMMOMAT(R) NovationDR, a ... Nevada Cancer Institute,s,(NVCI) new Hope Coach, a mobile digital ...
Cached Medicine News:Health News:BET Networks Special 'What U Know Bout That? Rap-It-Up Sex Quiz' HIV/AIDS To Premiere On Monday, November 5 At 7:30 P.M. ET/PT 2Health News:BET Networks Special 'What U Know Bout That? Rap-It-Up Sex Quiz' HIV/AIDS To Premiere On Monday, November 5 At 7:30 P.M. ET/PT 3Health News:BET Networks Special 'What U Know Bout That? Rap-It-Up Sex Quiz' HIV/AIDS To Premiere On Monday, November 5 At 7:30 P.M. ET/PT 4Health News:DaVita to Open First Independent Dialysis Clinic in Fargo-Moorhead 2Health News:Anthem Introduces New Insurance Options for Small Business 2Health News:Web-Based Stress Therapy Shows Promise for Vets 2Health News:Siemens Rolls Out Its First Mobile Digital Mammography System in the U.S. 2Health News:Siemens Rolls Out Its First Mobile Digital Mammography System in the U.S. 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: